HOME > 홍보/투자정보 > 산업동향
유전자치료제, 심혈관·망막질환 위주로 개발해야
ViroMed
2014/10/28
www.hkn24.com/news/articleView.html?idxno=137739
http://www.hkn24.com/news/articleView.html?idxno=137739